64a55883 Ada5 4769 E053 2a91aa0ae5f6
Clopidogrel
Product Images NDC 71717-101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71717-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Megalith Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Clopidogrel 01)
Image Description (Clopidogrel 02)
Image Description (Clopidogrel 03)
This appears to be a medical study or report comparing the incidence of cardiovascular death, myocardial infarction, and stroke in patients receiving either placebo or clopidogrel (in combination with aspirin) over a period of 12 months. The chart shows a significant reduction in the cumulative event rate for patients receiving clopidogrel compared to placebo, with a p-value of 0.00009.*
Image Description (Clopidogrel 04)
This is a statistical table showing various patient baseline characteristics and on-study concomitant medications/interventions for the CURE study. The characteristics include age, gender, race, cardiovascular health status, diabetes status, and medication usage such as Heparin/L MWH, Aspirin, GPIbIIIa Antag, Beta-Blocker, Ace Inhibitor, etc. The hazard ratio (95% CI) is also reported. More details on the specific results of the study are not available from this text.*
Image Description (Clopidogrel 05)
The text shows a comparison of the death rate between Placebo and Clopidogrel, which are two different treatments. The data mentions the number of deaths and the percentage of deaths for each treatment. The graph indicates the proportion of deaths before and after the treatment, as well as the days since randomization.*
Image Description (Clopidogrel 06)
Image Description (Clopidogrel 07)
This text provides a data table showing information about a medical study. The table includes data such as gender, age, hours since onset, SBP, heart rate and fibrinolytic agent given. The table also shows the numbers and percentages of patients who received Plavix or placebo along with, a statistical analysis of the data.*
Image Description (Clopidogrel 08)
Image Description (Clopidogrel 09)
Image Description (Clopidogrel Bottle Label 03)
This appears to be a prescription label for the medication Clopidogrel. The label includes information such as the medication strength (75 mg), dosage instructions, and the pharmacy's location.*
Image Description (Clopidogrel Bottle Label 09)
This is a package of 90 tablets of Clopidogrel, with NDC code 71717-101-03. The recommended adult dosage is 75mg per day. There is also a reference to "Darbussby" and "ROy eg".*
Image Description (Clopidogrel Bottle Label 50)
Clopidogrel is a medication available in tablet form with a strength of 75mg. The therapy is known for its properties in preventing blood clots and is primarily used for patients who have a higher risk of developing complications from cardiovascular disease. The medication is produced by Wngalin Pharmaceuticals, and it comes in a sex pack. The text also mentions the NDC code and the date of production.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
